(813) 971-8080

17554 Holly Well Ave., Tampa, FL 33598

commercial diet companies

GLP-1 Drugs Market Update

Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic.  The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The […]

GLP-1 Drugs Market Update Read More »

Trouble at Noom?

Feb. 3, 2022 As reported here and in many other publications, Noom’s rapid growth as a weight loss program is well known. The company may plan an IPO this year, and it’s estimated that revenues topped $600 million last year. The company has raised $669 million to date. However, there may be some weak spots.

Trouble at Noom? Read More »

Scroll to Top